Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetanus toxoid + diphtheria toxoid + inactivated poliovirus vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Tetanus toxoid + diphtheria toxoid + inactivated poliovirus vaccine** is a combination vaccine that induces active immunity against tetanus (caused by *Clostridium tetani* toxin), diphtheria (caused by *Corynebacterium diphtheriae* toxin), and poliomyelitis (caused by poliovirus types 1, 2, and 3). It contains detoxified tetanus and diphtheria toxoids to stimulate antibody production neutralizing the respective toxins, alongside inactivated poliovirus antigens for humoral and mucosal immunity against polio. Primarily used as a booster in adolescents and adults for maintaining protection, especially in regions like the UK where it is administered around age 14; toxoids are adsorbed onto aluminum adjuvant for enhanced immunogenicity, with no pertussis component distinguishing it from DTaP-IPV vaccines.
- Brand names
- DT-IPV
- Other names
- DT + IPVTd/IPV
02
Targets
Diphtheria toxinPRR (Pattern recognition receptors)
Beyond the preview
Go deeper on tetanus toxoid + diphtheria toxoid + inactivated poliovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetanus toxoid + diphtheria toxoid + inactivated poliovirus vaccine.